Asymmetric Dimethylarginine and Lipid Peroxidation Products in Early Autosomal Dominant Polycystic Kidney Disease

American Journal of Kidney Diseases

Volumn 51, Issue 2, 2008, Pages 184-191

  Wang, Dan ^a,b   Strandgaard, Svend ^b   Borresen, Malene L ^b   Luo, Zaiming ^a   Connors, Stephanie G ^a   Yan, Qing ^c   Wilcox, Christopher S ^a  

^a Cardiovascular Kidney Hypertension Institute   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

13 hydroxyoctadecadienoic acid (HODE); dimethylarginine dimethylaminohydrolases (DDAH); hypertension; Nitric oxide synthase (NOS); reactive oxygen species (ROS)

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; ARGININE; BIOLOGICAL MARKER; CREATININE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; STEARIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY POLYCYSTIC DISEASE; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; UNIVERSITY HOSPITAL; URINARY EXCRETION;

ADULT; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINOLEIC ACIDS; LIPID PEROXIDATION; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 38349070335     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.09.020     Document Type: Article

References (62)

1. Gabow P.A. Autosomal dominant polycystic kidney disease. Am J Kidney Dis 22 (1993) 511-512
2. Wang D., Iversen J., Wilcox C.S., et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64 (2003) 1381-1388
3. Wang D., and Strandgaard S. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 15 (1997) 925-933
4. Muto S., Aiba A., Saito Y., et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11 (2002) 1731-1742
5. Wang D., Iversen J., and Strandgaard S. Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney rats. J Vasc Res 36 (1999) 502-509
6. Wang D., Iversen J., and Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11 (2000) 1371-1376
7. Al-Nimri M.A., Komers R., Oyama T.T., et al. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 63 (2003) 1776-1784
8. Wang D., Braendstrup O., Larsen S., et al. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. Acta Pathol Microbiol Immunol Scand 112 (2004) 358-368
9. Clausen P., Feldt-Rasmussen B., Iversen J., et al. Flow-associated dilatory capacity of the brachial artery is intact in early autosomal dominant polycystic kidney disease. Am J Nephrol 26 (2006) 335-339
10. Borresen M.L., Wang D., and Strandgaard S. Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 27 (2007) 240-246
11. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13 (2002) 170-176
12. Torremans A., Marescau B., Kranzlin B., et al. Biochemical validation of a rat model for polycystic kidney disease: Comparison of guanidino compound profile with the human condition. Kidney Int 69 (2006) 2003-2012
13. Caglar K., Yilmaz M.I., Sonmez A., et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70 (2006) 781-787
14. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358 (2001) 2113-2117
15. Osanai T., Fujiwara N., Saitoh M., et al. Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. Blood Purif 20 (2002) 466-468
16. Kielstein J.T., Simmel S., Bode-Boger S.M., et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 27 (2004) 143-147
17. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90 (1992) 278-281
18. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2 (2006) 209-220
19. Himmelfarb J., Stenvinkel P., Ikizler T.A., et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
20. Aslam S., Santha T., Leone A., et al. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 70 (2006) 2109-2115
21. Oberg B., McMenamin E., Lucas F.L., et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65 (2004) 1009-1016
22. Paisley K.E., Beaman M., Tooke J.E., et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 63 (2003) 624-633
23. Valziri N.D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13 (2004) 93-99
24. Tain Y.L., Freshour G., Dikalova A., et al. Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 292 (2007) F1404-F1410
25. Leiper J., Murray-Rust J., McDonald N., et al. S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A 99 (2002) 13527-13532
26. Knipp M., Braun O., Gehrig P.M., et al. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation. J Biol Chem 278 (2003) 3410-3416
27. Boger R.H., Sydow K., Borlak T., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ Res 87 (2000) 99-105
28. Jiang D.-J., Jiang J.-L., Tan G.-S., et al. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Arch Pharmacol 367 (2003) 600-606
29. Knipp M. How to control NO production in cells: N(omega),N(omega)-dimethyl-l-arginine dimethylaminohydrolase as a novel drug target. Chembiochem 7 (2006) 879-889
30. Stühlinger M.C., Tsao P.S., Her J.H., et al. Homocysteine impairs the nitric oxide synthase pathway. Circulation 104 (2001) 2569-2575
31. Yin Q.F., and Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 45 (2005) 525-532
32. Iakoubova O., Dushkin H., and Beier D. Genetic analysis of a quantitative trait in a mouse model of polycystic kidney disease. Am J Respir Crit Care Med 156 (1997) 770-777
33. Maser R.L., Vassmer D., Magenheimer B.S., et al. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol 13 (2002) 991-999
34. Torres V.E., Bengal R.J., Litwiller R.D., et al. Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 8 (1997) 1283-1291
35. Belkner J., Wiesner R., and Kuhn H. Identification of oxidatively modified lipids in atherosclerotic lesions of human aortas. Agents Actions Suppl 37 (1992) S78-S84
36. Buchanan M.R., Haas T.A., Lagarde M., et al. 13-Hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX. J Biol Chem 260 (1985) 16056-16059
37. Spiteller P., and Spiteller G. 9-Hydroxy-10,12-octadecadienoic acid (9-HODE) and 13-hydroxy-9,11-octadecadienoic acid (13-HODE): Excellent markers for lipid peroxidation. Chem Phys Lipids 89 (1997) 131-139
38. Martensson J., Groth S., Rehling M., et al. Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med 39 (1998) 2131-2137
39. Wilcox C.S., Lewis P.S., Peart W.S., et al. Renal function, body fluid volumes, renin, aldosterone, and noradrenaline during treatment of hypertension with pindolol. J Cardiovasc Pharmacol 3 (1981) 598-611
40. Bachorik P.S., and Ross J.W. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: Executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 41 (1995) 1414-1420
41. Vallance P., Leone A., Calver A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
42. Browne R.W., and Armstrong D. Separation of hydroxy and hydroperoxy polyunsaturated fatty acids by high-pressure liquid chromatography. Methods Mol Biol 108 (1998) 147-155
43. Thomas C.E., and Jackson R.L. Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low density lipoproteins. J Pharmacol Exp Ther 256 (1991) 1182-1188
44. Benvenuti C., and Loisance D. Increased serum nitric oxide concentration in cardiac transplantation patients. A marker acute allograft cellular rejection. Transplantation 61 (1996) 745-749
45. -3 excretion as an indicator of nitrite oxide formation in vivo during oral administration of l-arginine and l-NAME in rats. Clin Exp Pharmacol Physiol Suppl 23 (1996) S11-S15
46. Sahai H., and Khurshid A. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: A review. Stat Med 15 (1996) 1-21
47. Agarwal R. Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol 61 (2004) 377-383
48. Knipp M., Charnock J.M., Garner C.D., et al. Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn(II) release activates DDAH-1. J Biol Chem 276 (2001) 40449-40456
49. Tojo A., Kimoto M., and Wilcox C.S. Renal expression of constitutive NOS and DDAH: Separate effects of salt intake and angiotensin. Kidney Int 58 (2000) 2075-2083
50. Nijveldt R.J., Van Leeuwen P.A., Van G.C., et al. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17 (2002) 1999-2002
51. Matsuguma K., Ueda S., Yamagishi S., et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17 (2006) 2176-2183
52. Welch W.J., and Wilcox C.S. Macula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure. Effects of salt intake. J Clin Invest 100 (1997) 2235-2242
53. Silbernagl S., and Deetjen P. Molecular specificity of the l-arginine reabsorption mechanism. Microperfusion studies in the proximal tubule of rat kidney. Pflugers Arch 340 (1973) 325-334
54. G dimethylarginine in renal insufficiency. Pflugers Arch 439 (2000) 524-531
55. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 (2004) 1023-1030
56. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol 20 (2000) 2032-2037
57. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
58. Fliser D., Kronenberg F., Kielstein J.T., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16 (2005) 2456-2461
59. Zeier M., Fehrenbach P., Geberth S., et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 42 (1992) 1259-1265
60. Yamada S.S., Sassaki A.L., Fujihara C.K., et al. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension 27 (1996) 1165-1172
61. Schaufele T.G., Schlaich M.P., Delles C., et al. Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney Int 70 (2006) 1177-1181
62. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16 (2005) 2449-2455